



# CONTINUITY OF NUTRITION CARE

optimal  
nutritional care  
for all

## THE POWER OF CONCERTED EFFORTS AGAINST MALNUTRITION



**A PAN-EUROPEAN APPROACH  
TO  
NUTRITION ECONOMIC RESEARCH**

**AMSTERDAM ONCA CONFERENCE**

**Jun 15, 2023**

**Mark Nuijten, PhD, MD. MBA**

**A2M - Minerva**

# OBJECTIVE

# Objective

---

- To present nutrition economic research from pan-European perspective.
- 
- Focus on malnutrition:
    - 1) Concepts: e.g. design of studies
    - 2) Practical application

# CONTEXT



# Context

---

## Epidemiology:

- The prevalence of people at risk of malnutrition is estimated at 20 million adults in the European Union (EU).
- Malnutrition is prevalent across all healthcare settings, particularly in patients in hospital, as well as prevalent across all age groups.
  - About 1 in 4 (18–34%) adult hospital patients are malnourished or at risk of malnutrition.
  - Among the elderly, a prevalence of malnutrition of 3.1% and a prevalence of risk of malnutrition of 26.5% was made.

# Context

---

## Clinical consequences:

- **Malnutrition has functional consequences in adults and older people:**
  - **Malnourished hospital patients experience significantly higher complication rates than well-nourished patients (30.6% vs. 11)**
  - **Significantly higher mortality rates have been found in “at-risk” hospital patients compared with “not-at-risk” patients (12% vs. 1%).**
  - **Poor Quality of Life (QoL) is also reported in malnourished surgical patients, patients with end-stage renal disease undergoing hemodialysis and in general admissions to the acute hospital setting.**

# Context

---

## **Economic consequences:**

- **Malnutrition is associated with increased healthcare resource use across all age groups.**
  - **Increase in length of hospital stay, readmissions and GP consultation. Average length of hospital stay may be increased by 30% in malnourished patients.**
  - **Higher readmission rates for after hospitalization.**
  - **The extra cost of treating a patient with malnutrition is 2 to 3 times higher than for a non-malnourished patient.**



# Context

---

## Impact MN:

- **Nutritional support, including oral nutritional supplements, enteral tube feeding and parenteral nutrition, can be an important part of the management of any patient:**
  - **Reduction complications**
  - **Reduction length of stay**
  - **Cost-effective**
  - **Increase Quality of Life**
  - **Reduction of hospitalisation costs**



# HEALTH ECONOMICS


# Pricing and Reimbursement

---

Safety, Efficacy &  
Quality




Clinical & Cost  
effectiveness



*'4th Hurdle'*

Affordability and  
impact on services



*'5th Hurdle'*

# Cost-Effectiveness

---

## Utility - QALY

- Survival, but also correction for Quality of Life
- Final (hard) endpoint between 0 and 1:
  - Dead: 0
  - Perfect health: 1

	Survival	Quality of Life	QALY
<b>Treatment A</b>	<b>8</b>	<b>0.5</b>	<b>4.0</b>
<b>Treatment B</b>	<b>5</b>	<b>0.9</b>	<b>4.5</b>

- Comparison across diseases: e.g. depression and asthma

# Cost-Effectiveness


## Cost-effectiveness:

- Incremental cost-effectiveness ratio - Cost per QALY
- $ICER = (Cost\_N - Cost\_U) / (Utility\_N - Utility\_U)$

	Survival	Quality of Life	QALY	Total costs	ICER
Treatment A	8	0.5	4.0	10,000	
Treatment B	5	0.9	4.5	15,000	
Difference			0.5	5,000	10,000

- Interpretation: extra Euro 10,000 to gain one year in perfect health!

# Cost-Effectiveness



$\frac{\text{Total costs}}{\text{Effectiveness (QALYs)}} < 80.000 \text{ euro}$



# Cost-Benefit Analysis

## Population based assessment

- Preventive programs: e.g screening
- Cost screening is € 4 million
- Total cost of case is € 12,000
- No screening: 10,000 \* € 12,000 is € 120 million
- Screening: 4,000 \* € 12,000 is 48 million+ € 4 million is 52 million

	Program	Cases	Cost case	Total costs	QALYs
No screening	0	10,000	12,000	120 million	Monetary
Screening	4 million	4,000	12,000	52 million	Monetary
Difference				68 million	

# Nutrition Economics

---

## Nutrition

- **Need of justification of evidence, but also increasingly need for health economic evidence**



- **No specific guidelines for execution of health economic evaluations.**

# Nutrition Economics

## Target audiences

Audience		Drug		Nutrition	Remark
society	ICER: cost per QALY	yes		unclear	no formal guidelines
central payor	ICER: cost per QALY	yes		unclear	no formal guidelines
health insurance comp	cost savings	yes		yes	
medical community	effectiveness	yes		yes	more difficult to convince
employer	lost productivity	yes		yes	
patient	payment nutrition/benefit ratio	NA		yes	

# PAN-EURPEOAN APPROACH MALNUTRITION

# PAN EU Approach


---

## **Development of European core model:**

- **Selection of pilot country, e.g. England, Netherlands.**
- **Model structure: 1) reflection most relevant treatment pathways I Europe: 2) country-specific finetuning (e.g. dummy zero, if not relevant).**
- **Data sources: 1) country-specific, 2) international**
- **Advisory Board - validation of model structure, data sources and assumptions.**

# PAN EU Approach

## European core model structure:





# PAN EU Approach

---

## Design

- Settings
- Prevalence malnutrition
- Comparison
- Screening malnutrition
- Clinical and economic consequences of malnutrition
- Management of malnutrition
- Impact of MN on malnutrition
- Costs of management malnutrition

# PAN EU Approach

## Selection of clinical and economic consequences:

- Setting
- Link to hard clinical outcome
- Perspective

clinical consequences		economic consequences	
complications - all		medical costs	
complications - minor			consultations dietician
complications - major			consultations GP
sepsis			consultations specialist
pneumonia			procedures
pressure ulcers			admissions
number of falls			re-admissions
mortality			LOS
life expectancy			% ICU and LOS - ICU
ADL			cost of episode
survival		indirect costs	lost productivity (days)
QALYs			
body weight		non-medical costs	transport
BMI			
hand grip strength			
Barthel index			

# PAN EU Approach

---

## Management malnutrition:

- Dietary advice
- Dietary advice + ONS

## Specified per setting:

- Hospital
- Nursing home - care home
- Community care - mainly elderly

# PAN EU Approach

---

## Impact of MN on malnutrition

- This depends on efficacy/effectiveness of MN on clinical outcomes, which have health economic consequences.
- Ideally use of data for each setting.
- In clinical trials MN is compared with “no treatment” or “diet and advice”.

# PAN EU Approach

---

## Different types of data

- **Epidemiology: prevalence of malnutrition** country-specific
- **Distribution of therapeutic choices: and use of MN in each healthcare setting** country-specific
- **Probabilities of clinical events, e.g. complications of malnutrition.** international
- **Effectiveness of MN** international
- **Economic benefits of MN** country-specific
- **Costing information** country-specific

# PAN EU Approach

---

## Sources


- Published literature
- Official Dutch price/tariff lists
- Population statistics
- Delphi Panel (optional).
  - To validate the assumptions and handling of data from the various sources
  - To estimate missing data, ideally limited to economic data



# PAN EU Approach

---

## Credibility



# CONCLUSION

# Conclusion

---

## PAN EU approach

- Economies of scale
- Consistency in approach for countries
- Comparison between outcomes of countries

**A PAN-EUROPEAN APPROACH  
TO  
NUTRITION ECONOMIC RESEARCH**

**AMSTERDAM ONCA CONFERENCE**

**Jun 15, 2023**

**Mark Nuijten, PhD, MD. MBA**

**A2M - Minerva**